Abstract
In recent months, three new non-steroidal anti-inflammatory drugs (NSAIDs), benoxaprofen (Opren), zomepirac (Zomax) and indoprofen (Flosint), and a new formulation of indomethacin (Osmosin), have been withdrawn because of their adverse effects. However, two of the older drugs in this group are also known to be particularly hazardous. Blood dyscrasias, mainly aplastic anaemia, associated with phenylbutazone and oxyphenbutazone were a major cause of drug-related death in reports to the Committee on Safety of Medicines (CSM) between 1964 and 1980.1Since many other NSAIDs are as effective the use of these two drugs is being reconsidered in many countries: in Norway they were banned last month.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
